JNJ-88545223
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 26, 2026
VELOTA: A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
(clinicaltrials.gov)
- P2 | N=75 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP
March 23, 2026
88545223PSA2001: A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis
(clinicaltrialsregister.eu)
- P1/2 | N=59 | Not yet recruiting | Sponsor: Janssen Cilag International
New P1/2 trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
January 17, 2026
VELOTA: A Study to Find Out How Effective and Safe JNJ-88545223 is for the Treatment of Participants With Active Psoriatic Arthritis (a Long-term Inflammatory Arthritis)
(clinicaltrials.gov)
- P2 | N=240 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP
1 to 3
Of
3
Go to page
1